Sucralose – properties of sweetener E955, health impacts, and potential hazards

In recent years, public awareness regarding the potential hazards associated with the consumption of artificial sugar substitutes has grown substantially. This shift is largely attributable to the rapid expansion of the functional food market, particularly low-calorie products that frequently incorporate controversial sweeteners. Among the most widely used are **high-fructose corn syrup** and **aspartame**, both of which have been linked to adverse health effects in extensive scientific research. A less recognized yet equally prevalent artificial sweetener in the food industry is **sucralose**, a chlorinated carbohydrate derivative identified on product labels as **E955** and commercially marketed under the brand name **Splenda**. Critically, the human metabolic system lacks the enzymatic pathways required to fully metabolize this compound. Instead, sucralose undergoes partial degradation into **toxic byproducts**, the accumulation of which has been associated with **carcinogenic properties**, as demonstrated in preclinical animal models. Furthermore, prolonged exposure to this sweetener may induce **thymic and splenic atrophy**, **hepatomegaly** (enlargement of the liver), **renal dysfunction**, and **growth inhibition**, particularly in developing organisms. A safer alternative to artificially sweetened "diet" products lies in **natural, sugar-free foods**, which can be sweetened independently using **stevia**—the only plant-based sweetener with a well-documented safety profile, additionally enriched with essential minerals such as magnesium, potassium, and chromium.

Recent clinical and preclinical investigations have shed substantial light on the metabolic ramifications of sucralose (E955) consumption. Initially marketed as a biologically inert, non-caloric sweetener that transits the gastrointestinal tract virtually unaltered, current scientific evidence demonstrates its capacity to significantly alter the microbial architecture of the human gut. Chronic exposure to sucralose induces intestinal dysbiosis, predominantly characterized by a quantitative reduction in beneficial commensal taxa such as *Bifidobacterium* and *Lactobacillus*, alongside an expansion of pro-inflammatory bacterial strains. Furthermore, interaction of sucralose with sweet taste receptors (T1R2/T1R3) on intestinal enterocytes enhances luminal glucose absorption via upregulated SGLT-1 transporter expression. Consequently, habitual consumers of artificially sweetened beverages and food items frequently experience impaired glucose tolerance and diminished peripheral insulin sensitivity, which over time elevates the clinical risk of developing metabolic syndrome and type 2 diabetes mellitus.

When eliminating synthetic sweeteners such as sucralose and aspartame from the diet, identifying evidence-based, natural alternatives is essential for sustained metabolic well-being. **Erythritol** represents one of the premier choices: a polyol with zero caloric value and a zero glycemic index, it is almost completely absorbed in the small intestine and excreted unchanged via the kidneys, thereby circumventing large-intestine fermentation and minimizing gastrointestinal discomfort. Another clinically validated substitute is **stevia** (*Stevia rebaudiana*), whose steviol glycosides (predominantly rebaudioside A) provide intense sweetness alongside mild antioxidant properties without eliciting insulinogenic responses. Additionally, **xylitol** (birch sugar), which contains 40% fewer calories than sucrose, exerts well-documented cariostatic effects by suppressing *Streptococcus mutans* proliferation and facilitating enamel remineralization. Progressively recalibrating the palate's sweet threshold while relying on whole-food sweetening agents ensures sustainable glycemic management without metabolic compromise.